Bladder Cancer VL

Bladder Preservation Protocols for Muscle-Invasive Urothelial Carcinoma - Arjun Balar

Details
Joining Alicia Morgans at ASCO GU is Arjun Balar, a bladder cancer expert at New York University, who speaks to the most recent clinical trials and the future direction of available regimens regarding bladder preservation protocols. For the past 30 years, muscle-invasive urothelial cancer patients have been given two options for treatment: radical cystectomy or cisplatinum. With the more recent av...

Weathering the Current BCG Shortage Crisis - Michael O’Donnell

Details
Michael O'Donnell shares his insight into managing the current BCG shortage crisis, highlighting ways to make the most out of the current supply and explains a few alternative intravesical agents that could be used in place of BCG for treating patients with bladder cancer. Dr. O'Donnell explains how risk can be assessed while prioritizing high-risk patients and shares advice as to how treatment pl...

Blue Light Cystoscopy with Cysview for Management of Non Muscle Invasive Bladder Cancer - Joshua Meeks

Details
Joshua Meeks joins Alicia Morgans to review his approach to cystoscopy using blue light and Cysview®, and how to best choose patients that will maximally benefit from that kind of technology. Dr. Meeks and Dr. Morgans also review the new approval of pembrolizumab in the BCG unresponsive high-risk non-muscle invasive bladder cancer (NMIBC). Biographies: Josh J. Meeks, MD, Ph.D., Assistant Professor...

Implications of the Bacillus Calmette-Guérin (BCG) Shortage - Joshua Meeks

Details
Joshua Meeks joins Alicia Morgans to discuss the current BCG shortage and its implications for treatment options in the bladder cancer community. Dr. Meeks highlights clinical data on the matter presented by other clinicians at the conference, as well as his own personal expertise on how he manages the patient selection and the risk stratification process for BCG resources in his own clinic. Biogr...

Improving Research and Clinical Care, Bladder Cancer in Women - Jean Hoffman-Censits

Details
Medical Oncologist and co-leader of the Women's Bladder Cancer Program at John Hopkins, Jean Hoffman-Censits joins Alicia Morgans to speak about bladder cancer in women and the initiatives and importance of the Women's Bladder Cancer Program. In many cases, there are significant delays in diagnosing bladder cancer in women. Dr. Hoffman-Censits discusses the continuous narrative of the delay in dia...

Current and Emerging Therapies for Non-Muscle Invasive Bladder Cancer after BCG - Chris Wallis & Zach Klaassen

Details
For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...

Phase III Nadofaragene Firadenovec for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Joshua J. Meeks

Details
In this discussion, Josh Meeks joins Alicia Morgans to review the new advances phase III Nadofaragene Firadenovec (Adstiladrin®) trial for BCG unresponsive non-muscle invasive bladder cancer patients. Dr. Meeks details the results of this recently presented trial data and why he believes this is the beginning of the next era in treating these patients. Biographies: Josh J. Meeks, MD, Ph.D., Assist...

The BCG Shortage - What To Do In This Setting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the current shortage of Bacille Calmette-Guérin (BCG) and how it is impacting clinicians' treatment decisions and ongoing clinical trials. Dr. Meeks shares his thoughts behind the shortage and provides his strategy for clinicians and teams to make the proper patient selection to use the available BCG effectively to cover as many patients as possible. Biograp...

Advancements in BCG Unresponsive Bladder Cancer: Highlights from the 2019 SUO Meeting - Joshua Meeks

Details
Alicia Morgans and Joshua Meeks discuss the recent advancements in treating Bacille Calmette-Guérin (BCG) unresponsive bladder cancer that came from the 2019 meeting of the Society of Urologic Oncology. They review the many promising clinical trials including some early data from the Phase III VICINIUM trial as well as a promising combination intravesical chemotherapy options for non-muscle-invasi...

A New Era In Systemic Therapies, Pembrolizumab for High Risk Non-Muscle Invasive BCG-Refractory Patients - Arjun Balar

Details
Arjun Balar and Alicia Morgans discuss the new era in systemic therapies in non-muscle invasive bladder cancer (NMIBC) focusing on the systemic checkpoint inhibitor, pembrolizumab that resulted in the US FDA approval of pembrolizumab for treatment in early bladder cancer. Historically being in the domain of urologic oncologists, Drs. Morgans and Balar discuss the importance of the medical oncologi...
email news signup